Weekly Spotlight - 14.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Eque-Cel CAR T Shows Strong Results for Multiple Myeloma

Eque-Cel CAR T therapy shows promise for multiple myeloma, with strong responses in a Chinese study. Patients experienced early, deep, and durable responses, with a high overall response rate. Despite some adverse events, the therapy offers hope, especially for those naive to CAR T treatments.

Cancer cell therapy from Arcellx, Gilead shows promise in early data

Arcellx and Gilead's cancer cell therapy shows promise, reducing multiple myeloma signs in 95% of advanced cases without causing movement disorders. This therapy, anito-cel, offers hope as a safer alternative to Carvykti, potentially appealing to patients and doctors. Analysts remain divided on its overall efficacy.

J&J seeks regulatory nod for Darzalex Faspro's new indication in US & EU

Johnson & Johnson seeks approval for Darzalex Faspro's new use in the US and EU, targeting high-risk smouldering multiple myeloma. Based on the AQUILA study, this could become the first approved treatment for this condition, offering hope for early intervention and potentially changing the treatment landscape.

Victory as Myeloma UK Wins IsaPD Appeal

Myeloma UK successfully appealed NICE's decision to withdraw IsaPD, a vital myeloma treatment. The appeal highlighted unfair review processes due to system changes. IsaPD, crucial for extending patients' lives, remains available during the review. Patients and advocates urge NICE to reconsider, emphasising IsaPD's life-changing impact and necessity.